Shares of G1 Therapeutics plunged 46% after disappointing results from their Phase 3 trilaciclib combination trial for triple-negative breast cancer. ...
Rail Vision has unveiled its next-generation AI-based computer, aimed at enhancing railway safety and preventing accidents by detecting potential hazards. ...